Skip to content

Brain Recovery With Automated VEntilation

Effectiveness, Safety and Efficacy of Closed-Loop Ventilation in Acute Brain Injury-Patients

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06367816
Acronym
BRAVE
Enrollment
20
Registered
2024-04-16
Start date
2024-04-11
Completion date
2024-12-31
Last updated
2026-03-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Brain Injuries, Acute, Respiration, Artificial, Automation

Brief summary

Thus far, the closed-loop ventilation mode INTELLiVENT-ASV has been extensively tested in various groups of critically ill patients, and has been shown to be effective and safe in various groups of ventilated patients, including those at risk of acute respiratory distress syndrome (ARDS), patients with ARDS, and patients with chronic obstructive pulmonary disease (COPD). Some of these studies included acute brain injury (ABI) patients, but the effectiveness, efficacy and safety of INTELLiVENT-ASV has never been thoroughly tested in these patients. The current study will investigate the effectiveness in providing both brain- and lung protective ventilation, the safety and the efficacy of a closed-loop ventilation mode (INTELLiVENT-ASV) in acute brain injury patients, using breath-by-breath data.

Detailed description

Rationale: Closed-loop ventilation has been proven effective in lung-protective ventilation but its effectiveness, safety and efficacy in providing both lung- and brain-protective ventilation in patients with acute brain injury has not been investigated. Objective: To evaluate the effectiveness, efficacy and safety of INTELLiVENT-ASV with respect to brain- and lung-protective ventilation in ABI patients Hypothesis: We hypothesize that INTELLiVENT-ASV is effective with regard to brain- and lung-protective ventilation (that is achieving brain- and lung- protective targets), efficacious (that is improving outcomes), and that INTELLiVENT-ASV is safe in invasively ventilated ABI patients. Study design: Single-center, crossover trial. Methods: In this prospective observational study, breath-by-breath ventilation data will be available from before and after the switch to closed-loop ventilation with INTELLiVENT-ASV, wherein the decision to switch is determined by the attending healthcare worker, i.e., not protocolized and only for clinical/organizational reasons. High granular data are collected both before and after this switch, limited to three hours for conventional and three hours for closed-loop ventilation. Neuromonitoring is part of current clinical practice and data will be collected only when available. Study population: Invasively ventilated patients diagnosed with acute brain injury Methods: When the ventilator is switched upon the caregivers decision, data will be collected from three hours before the switch and three hours after the switch. Study endpoints: The primary composite endpoint is the proportion of breaths and proportion of time within predefined zones of ventilation (based on VT and airway pressures, saturation of peripheral O2 (SpO2) and end-tidal CO2 (EtCO2).

Interventions

PROCEDUREINTELLiVENT

Closed-loop mode of ventilation

Mode of ventilation

Sponsors

University of Genova
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 105 Years
Healthy volunteers
No

Inclusion criteria

* aged ≥ 18 years; * intubated and receiving invasive ventilation for ABI; * admitted to the Intensive Care Unit

Exclusion criteria

\- receiving ventilation with a ventilator that does not allow INTELLiVENT-ASV

Design outcomes

Primary

MeasureTime frame
Proportion of breaths in predefined zones of ventilation7 hours from baseline
Proportion of time in predefined zones of ventilation7 hours from baseline

Secondary

MeasureTime frame
Intracerebral changes assessed by multimodal neuromonitoring available7 hours from baseline
Changes on Electrical Impedence Tomography when available7 hours from baseline
Effectiveness in primary ABI patients vs non primary ABI patients7 hours from baseline
Episodes and time of high maximum airway pressure7 hours from baseline
Episodes and time of high respiratory rate7 hours from baseline
Incidence of severe hypoxemia7 hours from baseline
Incidence of severe hypercapnia7 hours from baseline
Discontinuation of ventilatory mode (yes or no)7 hours from baseline
Percentage of breaths in the predefined 'critical' ventilation zone7 hours from baseline
Incidence of pneumothorax8 hours from baseline
Efficacy on glascow coma scale7 hours from baseline
Duration of ventilation in survivors90 days
Ventilator free days90 days
Intensive care unit length of stay90 days
Hospital length of stay90 days
28-day mortality90 days
90-day mortality90 days
Number of alarms7 hours from baseline
Number of manual adjustments7 hours from baseline

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 11, 2026